Status:
RECRUITING
Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans
Lead Sponsor:
VA Office of Research and Development
Collaborating Sponsors:
University at Buffalo
Conditions:
Sarcopenia
Nicotinamide Adenine Dinucleotide Concentration
Eligibility:
All Genders
65-85 years
Phase:
NA
Brief Summary
Frailty is an age-associated clinical condition of poor physiological reserve that increases risks for falls, hospitalization and mortality. Nicotinamide adenine dinucleotide (NAD) is a critical co-fa...
Detailed Description
Frailty is increasingly seen within the aging population and is driven largely by musculoskeletal declines. Nearly 9 million Veterans are now 65 years of age or older with impairments in functional ca...
Eligibility Criteria
Inclusion
- Ages 65-85
- Male or female
- Any race
- Ability to use an exercise bike
- Medically cleared for muscle biopsy
Exclusion
- Severe Co-morbidity
- examples include, but not limited to:
- congestive heart failure class equal to or above III
- chronic obstructive pulmonary disorder (COPD) gold stage IV
- chronic kidney disease equal to or above stage
- A VA-SLUMS cognitive screen score of less than or equal to 20
- Body mass index greater than or equal to 40
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT04691986
Start Date
September 1 2023
End Date
June 30 2026
Last Update
October 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kansas City VA Medical Center, Kansas City, MO
Kansas City, Missouri, United States, 64128-2226